Morgan Stanley’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,905
| Closed | -$17K | – | 6863 |
|
|
2019
Q4 | $17K | Buy |
1,905
+1,844
| +3,023% | +$22.4K | ﹤0.01% | 6147 |
|
|
2019
Q3 | $1K | Sell |
61
-931
| -94% | -$13.9K | ﹤0.01% | 6602 |
|
|
2019
Q2 | $13K | Buy |
992
+768
| +343% | +$11.5K | ﹤0.01% | 6071 |
|
|
2019
Q1 | $3K | Sell |
224
-6,362
| -97% | -$92.6K | ﹤0.01% | 6426 |
|
|
2018
Q4 | $145K | Buy |
6,586
+6,578
| +82,225% | +$121K | ﹤0.01% | 5412 |
|
|
2018
Q3 | $0 | Sell |
8
-1
| -11% | -$14 | ﹤0.01% | 6895 |
|
|
2018
Q2 | $0 | Sell |
9
-780
| -99% | -$15.7K | ﹤0.01% | 6819 |
|
|
2018
Q1 | $16K | Buy |
789
+621
| +370% | +$12.2K | ﹤0.01% | 6176 |
|
|
2017
Q4 | $3K | Sell |
168
-213
| -56% | -$4.95K | ﹤0.01% | 6419 |
|
|
2017
Q3 | $7K | Sell |
381
-158
| -29% | -$3.79K | ﹤0.01% | 6247 |
|
|
2017
Q2 | $14K | Buy |
539
+446
| +480% | +$14.4K | ﹤0.01% | 6172 |
|
|
2017
Q1 | $3K | Buy |
+93
| New | +$3.43K | ﹤0.01% | 6434 |
|
|
2016
Q3 | – | Sell |
-2,795
| Closed | -$181K | – | 6604 |
|
|
2016
Q2 | $181K | Sell |
2,795
-2,574
| -48% | -$158K | ﹤0.01% | 4991 |
|
|
2016
Q1 | $389K | Buy |
5,369
+4,680
| +679% | +$347K | ﹤0.01% | 4592 |
|
|
2015
Q4 | $28K | Buy |
+689
| New | +$33.9K | ﹤0.01% | 5933 |
|
Other funds holding ZBIO
Morgan Stanley's ZBIO Position: Q1 2020 in Review
Morgan Stanley sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q1 2020, closing a stake of 1,905 shares — an estimated $17K sold.
Morgan Stanley first reported a position in ZBIO in Q4 2015 and held it in 15 quarters. The position peaked at $389K in Q1 2016. 1 fund tracked by Wall St. Rank holds ZBIO as of Q1 2020.
- Morgan Stanley reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Morgan Stanley sold 1,905 ProShares UltraPro Short NASDAQ Biotechnology shares in Q1 2020, an estimated $17K.
- Morgan Stanley first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q4 2015 and held it in 15 quarters.
- Morgan Stanley's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $389K in Q1 2016.
- 1 fund tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q1 2020.
Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.